Department of Hematology, Jagiellonian University Medical College, Cracow, Poland.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Leuk Lymphoma. 2020 Aug;61(8):1885-1893. doi: 10.1080/10428194.2020.1749605. Epub 2020 Apr 19.
The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients - 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) ( = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively ( = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT ( < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24-3.19; = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).
MAF 易位，t(14;16)和 t(14;20)，基于少数样本量小的研究被认为是不良预后因素。我们报告了在一个由 254 名患者组成的大组中（223 名（87.8%）有 t(14;16)，31 名（12.2%）有 t(14;20)），他们的预后影响。在生存估计方面没有组间差异。t(14;16)的无进展生存中位数为 16.6 个月，t(14;20)的无进展生存中位数为 24.9 个月（=0.28）。中位总生存期（OS）分别为 54.0 个月和 49.0 个月（=0.62）。接受双自体干细胞移植（ASCT）的患者中位 OS 为 107.0 个月，而仅接受单 ASCT 的患者中位 OS 为 60.0 个月（<0.001）。Cox 分析显示，ISS3 与较短的 OS 相关（HR=1.89；95%CI1.24-3.19；=0.005）。我们的研究表明，t(14;20)应被视为与 t(14;16)具有同等预后意义的不良因素。
